|
Syncona Ltd on Wednesday noted its investee Beacon Therapeutics Holdings Ltd received positive data from its trial of laru-zova for the treatment of patients with X-linked retinitis pigmentosa. Synocona is a London-based investor in healthcare companies. Beacon Therapeutics is a Florida, US-based ophthalmic gene therapy company. Beacon’s phase 2 Dawn trial of lead programme laru-zova, or laruparetigene zovaparvovec, saw improvements in patients across several key visual function measures, demonstrating the drug’s potential to enhance vision in XLRP patients. Laru-zova was also ‘generally well-tolerated’ by patients in the Dawn trial at the six-month mark. ‘We are really pleased with the progress at Beacon. It is fantastic to see continued visual improvements in patients evaluated at the six-month time point in this data update,’ said Elisa Petris, partner of Syncona Investment Management Ltd and board director at Beacon Therapeutics. ‘We are optimistic as the company progresses enrollment for its Phase 2/3 pivotal study and look forward to seeing data in this crucial programme. We see a really differentiated opportunity with this therapy to transform the lives of patients with a devastating retinal blinding condition.’ Syncona shares were flat at 90.00 pence each in London on Wednesday morning. The stock is down 26% over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
